The traditional Chinese medicine sector is active again, and stocks such as Longjin Pharmaceutical have opened their daily limit

[Pharmaceutical Network Pharmaceutical Stock Market] On February 14th, the traditional Chinese medicine sector was active again
.

In terms of individual stocks, Longjin Pharmaceuticals, Essence Pharmaceuticals, etc.
opened the daily limit, Shanghai Kaibao rose by more than 8%, Longshen Rongfa, Xintian Pharmaceutical, Zhongsheng Pharmaceutical, and Taiji Group rose by more than 3%.
In addition, Pien Tze Huang, Foci Pharmaceuticals and others also followed suit
.

Longjin Pharmaceutical: Opening the daily limit since the end of 2021, Longjin Pharmaceutical has closed more than ten daily limit
.

At 9:57 on February 14, Longjin Pharmaceutical once again closed the price limit, now reporting 13.
92 yuan, with a turnover of 488 million and a turnover rate of 9.
00%
.

Longjin Pharmaceutical is mainly engaged in the development and production of natural herbal medicines and freeze-dried powder injections of chemicals
.

In the first three quarters of 2021, Longjin Pharmaceutical's net profit attributable to shareholders of listed companies was 5.
0839 million yuan to 7.
6259 million yuan, a year-on-year increase of 122.
52% to 233.
78%
.

 　　On the news, the company recently issued a progress announcement on the use of idle self-owned funds for cash management.
The company reviewed and approved the "Proposal on Using Idle Self-owned Funds for Cash Management", agreeing that the company and its holding subsidiaries use the balance of no more than RMB 3.
5.
RMB 100 million of self-owned idle funds for cash management, investment products include structured deposits, wealth management products, income certificates, monetary funds, treasury bonds, reverse repurchase of treasury bonds and other products with medium and low risks, which ensure the safety of principal and good liquidity.
The company shall not have any associated relationship with financial institutions that provide cash management products
.

 　　Essence Pharma: Hit the daily limit Essence Pharma hit the daily limit on February 14 and is now at 12.
46 yuan, with a turnover of 630 million and a turnover rate of 6.
11%
.

The stock has risen by the limit 20 times in the past year
.

 　　The company is mainly engaged in the research and development, production and sales of traditional Chinese patent medicine preparations, chemical raw materials and intermediates, chemical and pharmaceutical intermediates, Chinese herbal medicines and Chinese herbal decoction pieces, and biopharmaceuticals
.

The third quarterly report shows that in the first three quarters of 2021, the company's main income was 969 million yuan, a year-on-year increase of 4.
69%; the net profit attributable to the parent was 128 million yuan, a year-on-year increase of 26.
32%
.

 　　Regarding the reasons for the stock price change, the analysis believes that, first, Essence Pharma stated on the interactive platform that the planned annual production capacity of Nantong Senxuan ritonavir series intermediates of the company's subsidiary company is 230 tons.
The average capacity utilization rate is between 10% and 30%; secondly, the company relies on superior products to vigorously develop the market for Chinese patent medicine products
.

In addition, Wang's Baochi Pills and Jidesheng She Pills are classified as national secret Chinese medicine varieties, while Wang's Baochi Pills, Jinqiaowheat Tablets and Guben Kechuan Tablets are national second-class TCM protected varieties
.

 　　Shanghai Kaibao: Up by more than 8% As of 10:34 on February 14, Shanghai Kaibao rose by more than 8%, and is now at 6.
50 yuan, with a turnover of 545 million and a turnover rate of 9.
08%
.

At the close on February 11, Shanghai Kaibao closed at 6.
02 yuan, down 7.
81%, with a turnover rate of 9.
46%, a trading volume of 867,100 lots, and a turnover of 533 million yuan
.

 　　Shanghai Kaibao is a comprehensive pharmaceutical company mainly engaged in the R&D, production and sales of modern Chinese medicines
.

The company's 2021 annual performance forecast shows that the company's net profit attributable to shareholders of listed companies in 2021 will be 138 million-170 million yuan, an increase of 30%-60% over the same period of the previous year
.

 　　On the news, the company recently issued an announcement that Zhang Tao, the deputy general manager of the company, increased his holdings of the company's shares by 11,100 shares through centralized bidding transactions
.

According to the announcement, before the increase in holdings, Zhang Tao held a total of 4,400 shares of the company, accounting for 0.
0004% of the company's total common stock
.